ModifiedCentenePolicy CP.PMN.59

Quantity Limit Override and Dose Optimization

Defines medical necessity criteria and authorization requirements for overriding pharmacy quantity limits (QL) and for dose optimization for Centene-affiliated health plans; applies to providers requesting exceptions for members covered under the plans (including Medicaid, HIM).

Policy Summary

PayerCentene

PolicyQuantity Limit Override and Dose Optimization

Policy CodePolicy CP.PMN.59

Change TypeMaterial updates and clarifications

Effective DateMay 1, 2014

Next Review Date

Key ActionSubmit prior authorization with documentation demonstrating criteria are met when requesting quantity limit or dose optimization exceptions.

SourceLink

POLICY UPDATE CHANGES

Added quantity limit exception criteria specific to acute therapies, with requirements for epinephrine and other acute therapies; removed criteria set for opioid QL exceptions as section I.A. will be applied.

For quantity limit exceptions (Section I.A.), clarified requirements for dose titration and optimization do not apply to requests for epinephrine in the treatment of allergic reactions.

Added disclaimer that medical management techniques, including quantity management, beyond step therapy is not allowed for members in NV per SB 439.

Revised continuity of care verbiage to state State or health plan continuity of care programs apply to the requested drug and indication with documentation that supports that member has received this medication for at least 30 days.

Added HIM line of business.

3Acute therapy approval (months)

12Typical approval (months)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

I. Initial Approval Criteria — Quantity Limit Exceptions and Dose Optimization

Quantity limit exceptions and dose optimization exceptions are medically necessary when ALL of the following are met as specified below.

Initial Quantity Limit Exceptions: Refer to Section IB for continuity of care and Section IC for pain management. Request must meet all listed conditions.

Acceptable rationales for QL exception: One of the following: (a) Requested dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); (b) Diagnosis of a rare condition/disease for which FDA dosing indicates a higher quantity than the currently set QL (example: Zollinger-Ellison syndrome allowing 2 doses/day for PPIs); (c) Request is for epinephrine in the treatment of allergic reactions with required documentation per epinephrine rules; (d) Other acute therapies (e.g., albuterol) where medical justification supports a higher quantity than QL (provider must submit documentation regarding current or planned maintenance therapies).

Non-epinephrine additional requirements: For requests other than epinephrine for allergic reactions, BOTH of the following must be met: (a) Member has been titrated up from the lower dose with partial improvement without adverse reactions; (b) Dose optimization is required unless i) dose titration: multiple lower-strength units are requested for the purpose of dose titration, or ii) other clinical reasons: medical justification supports inability to use the higher strength units to achieve the desired dose/regimen.

Dose optimization criteria: Dose optimization exceptions must meet either: (a) dose titration (multiple lower-strength units requested for purpose of titration) OR (b) other clinical reasons where medical justification supports inability to use higher-strength units. Additionally, the request must either not exceed the FDA-recommended regimen and maximum daily dose, or for QL exceptions follow Section I.A.

inv-05: Quantity limit exceptions — acute therapies

Covered when meeting updated quantity limit exception criteria

QL exception for acute therapies: Requests for acute therapies follow the added acute therapy-specific QL exception criteria; epinephrine has specific requirements adopted from CP.PMN.144. For epinephrine, provider must submit documentation of prior use with dates and associated medical/hospital care OR documentation that the most recent fill has expired, including expiration date.

Dose titration and optimization requirements do not apply to epinephrine requests for treatment of allergic reactions.

inv-23: Initial therapy

Initial approval criteria and acceptable rationales for QL override or dose optimization.

Guideline-supported dosing: Requested dose supported by practice guidelines or peer-reviewed literature; prescriber must submit supporting evidence.

Rare diagnosis requiring higher dosing: Diagnosis of a rare condition for which FDA dosing indicates higher quantity than QL (example: Zollinger-Ellison syndrome for PPIs).

Epinephrine rationale: Epinephrine requests for allergic reactions require documentation: either prior use with dates and associated immediate medical/hospital care, or that the most recent fill/device has expired with the expiration date documented.

Other acute therapy rationale: Other acute therapies require medical justification supporting higher quantity than the currently set QL and documentation regarding current or planned maintenance therapies.

inv-04: II. Continued Therapy

Continuation for epinephrine/acute therapies: Continuation of epinephrine or acute therapies will not be granted; member must be evaluated against the initial approval criteria.

Approval duration: Not applicable.

Continuation for other requests: Member must meet one of the following: (a) currently receiving medication via Centene benefit; (b) member has previously met initial approval criteria; or (c) state or health plan continuity of care applies with documentation that member received medication for at least 30 days. Member must be responding positively to therapy. Dose optimization is required unless documentation supports continued need for dose titration or medical justification prevents use of higher-strength units. For dose optimization requests that are dose increases, new dose must not exceed FDA-recommended regimen and maximum daily dose.

Approval duration: 12 months (60 days if dose titration).

inv-03: III. Dose Optimization Exceptions — Approval Durations

Dose titration duration: Dose titration exceptions: approval duration is duration of request or 60 days, whichever is less.

Other clinical reasons duration: Other clinical reasons exceptions: approval duration is duration of request or 12 months, whichever is less.

For members in Nevada, medical management techniques — including quantity management beyond step therapy — are not allowed for medication-assisted treatment (MAT)/withdrawal, HIV, and hepatitis C medications. This limitation means the plan will not apply additional quantity controls or other utilization management approaches that go beyond established step therapy requirements for these drug categories for Nevada members.

Requests that would otherwise invoke quantity management beyond step therapy for the specified therapies must be evaluated consistent with Nevada restrictions; providers should submit documentation per standard prior authorization processes but should expect that additional quantity-based medical management beyond step therapy is not permitted under Nevada law or policy.

Per Nevada law (SB 439) and the policy update, medical management techniques, including quantity management beyond step therapy, are not allowed for members in Nevada. This statewide limitation applies broadly and is specifically noted for therapies where such management would otherwise occur.

When submitting requests for Nevada members, providers should be aware that any authorization pathways or clinical criteria that would impose quantity management beyond step therapy cannot be used; continuity of care and other state or plan-required programs remain applicable where specified.

Continuity of Care

inv-02: B. Continuity of Care

Continuity of care exceptions apply when ALL of the following are met.

Continuity of Care criteria: (1) State or health plan continuity of care programs apply to the requested drug and indication (examples: seizures, heart failure, HIV, psychotic disorders, oncology, depression, transplant); (2) therapy will be titrated to the currently set QL; (3) dose optimization is required unless dose titration (multiple lower-strength units requested for titration) or other clinical reasons support inability to use higher-strength units.

Approval duration: 3 months (60 days if dose titration) or 12 months if subject to state continuity of care program.

inv-06: Continuity of care coverage

Covered under continuity of care when documentation supports prior therapy

Continuity of care: State or health plan continuity of care programs apply to the requested drug and indication when documentation shows the member received the medication for at least 30 days.>= 30 days

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required for quantity limit (QL) exceptions and for requests involving dose optimization. Providers must submit a prior authorization request and supporting clinical documentation showing the medical necessity for quantities or dosing that exceed the plan QL or that require consolidation of multiple lower-strength units into higher-strength commercial products. Requests that do not demonstrate dose optimization when commercially available higher strengths exist may be denied.

Applies to QL exception requests and dose-optimization overrides
See Section I.A for quantity limit exception criteria and Section I.C for dose optimization criteria

Note

Medicaid Precedence

For Medicaid members, state Medicaid coverage provisions take precedence over this clinical policy when there is a conflict. Provider should follow state Medicaid manual guidance for any differing coverage requirements.

Step Therapy Rules

Step	Requirement	Notes
1	Dose optimization is required unless dose titration or other clinical reasons justify multiple lower-strength units	Requests for multiple units of a lower strength will be denied when the plan‑approved QL is exceeded and higher‑strength units are commercially available to achieve the desired dose/regimen

Jurisdiction	Restriction	Implication
Nevada	Medical management techniques, including quantity management beyond step therapy, are not allowed per SB 439	Requests that apply such techniques for NV members may be denied; continuity of care/interacting policies must follow state law

Quantity Limits and Approval Durations

Epinephrine devices — allowed device pack quantities

Allowed epinephrine pack quantitiesOne Auvi-Q 2-pack, one EpiPen 2‑pack, one EpiPen Jr 2‑pack, or one Neffy 2‑pack

Policy sourceEpinephrine device quantities specified in quantity limits section

Continuation noteContinuation of epinephrine will not be granted; member must be evaluated against initial approval criteria

Acute therapies — approval duration and overrides

Approval duration for acute therapies3 months (acute therapies such as albuterol)

QL override possibilityQuantity limit override may be granted with medical justification and required documentation

Coding and Identifiers

Continuity of care duration (key threshold)

Continuity duration (codified threshold)>= 30 days

Use casesApplies to continuity of care coverage for specified indications (e.g., seizures, heart failure, HIV, psychotic disorders, oncology, depression, transplant)

Documentation requirementDocumentation must support that member received the medication for at least the threshold duration

Definitions

Dose optimization — definition

Dose optimization definitionConsolidation of multiple units of lower strength to the fewest units required to achieve the desired daily dose/regimen based on commercially available dosage strengths

PurposeReduces pill burden, simplifies regimens, improves adherence, and may reduce pharmacy spend

Denial riskRequests for multiple lower‑strength units will be denied when plan‑approved QL is exceeded and commercially available higher‑strength units can achieve the dose

Quantity limit (QL) — definition

QL (Quantity Limit) definitionQuantity limit (QL) — a plan‑approved limit on the quantity of a drug that may be dispensed within a specified time period

Relation to dose optimizationQLs interact with dose optimization: requests exceeding QL may require consolidation to higher‑strength units when commercially available

Background

Dose optimization is the clinical practice of consolidating multiple lower-strength units into the fewest higher-strength units needed to achieve the desired daily dose based on commercially available strengths. The goal is to reduce pill/device burden and pharmacy spend while ensuring the member receives the therapeutically equivalent total daily dose.

Under this policy, dose optimization exceptions are considered when either dose titration is occurring (multiple lower-strength units requested temporarily for titration) or when other clinical reasons justify inability to use higher-strength units. Requests must not exceed FDA-recommended regimens and maximum daily doses and must meet the applicable documentation requirements to support the medical necessity of the exception.

Providers requesting quantity limit overrides or dose optimization must submit clinical documentation (such as office notes, prior use history, or supporting literature) demonstrating the rationale — for example, guideline-supported dosing, rare diagnoses requiring higher doses, epinephrine use with prior-device documentation, or acute therapy justification — and should expect approval durations that vary by circumstance (e.g., short duration for titration vs. longer durations for other clinical reasons).

Continuation Criteria

inv-24: Continuation therapy — rules depend on therapy category

Continuation therapy — rules depend on therapy category.

Epinephrine/acute therapies: Continuation will not be granted; member must be re-evaluated against initial criteria.

Approval duration: Not applicable.

All other drugs: Continuation requires current receipt via Centene, prior meeting of initial criteria, or continuity of care documentation of >=30 days; member must be responding; dose optimization requirements apply unless continued titration or medical justification prevents use of higher-strength units. For dose increases, new dose must not exceed FDA-recommended regimen and maximum daily dose.

Approval duration: 12 months (60 days if dose titration).

Policy Summary

PayerCentene

PolicyQuantity Limit Override and Dose Optimization

Policy CodePolicy CP.PMN.59

Change TypeMaterial updates and clarifications

Effective DateMay 1, 2014

Next Review Date

Key ActionSubmit prior authorization with documentation demonstrating criteria are met when requesting quantity limit or dose optimization exceptions.

SourceLink

On This Page

Documentation Required

Documentation Requirement

Provider must submit supporting clinical documentation (such as office chart notes, labs, prior fill history, practice guideline citations or peer-reviewed literature) that demonstrates the member meets all approval criteria. Documentation must specifically address the rationale for requested quantity, evidence of prior trials/titration when applicable, and any safety or intolerance concerns that preclude use of higher strength commercial products.

Examples: office notes, lab results, medication administration records, prior authorization forms, peer-reviewed references for off-label dosing

Documentation Required

Epinephrine — Required Documentation

Epinephrine-specific documentation is required for QL overrides: provider must submit evidence of prior fills and clinical use (dates of administration and whether immediate medical or hospital care was received) or documentation that the previously dispensed device has expired (include expiration date). Epinephrine requests are exempt from dose-titration/dose-optimization rules when submitted under the specific epinephrine criteria.

Acceptable evidence: pharmacy fill history showing Auvi-Q, EpiPen, EpiPen Jr, or Neffy fills and dates of use, emergency care records if used, or device expiration documentation
Dose-titration/optimization criteria do not apply to epinephrine requests per policy